UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.611-622

2009

Link zum Volltext

Verfügbarkeit prüfen

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2564-2569

2019

Link zum Volltext

Verfügbarkeit prüfen

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.891-899

Davis, T. M. E.

2014

Link zum Volltext

Verfügbarkeit prüfen

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Archives of Endocrinology and Metabolism, 2018-08, Vol.62 (4), p.424-430

2018

Link zum Volltext

Verfügbarkeit prüfen

Baseline differences in the SAVOR trial

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1202-1202

2015

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes, obesity & metabolism, 2012-06, Vol.14 (6), p.481-492

2012

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria

Revista española de cardiología (English ed.), 2017-12, Vol.70 (12), p.1143-1144

2017

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin efficacy

Diabetes, obesity & metabolism, 2010-08, Vol.12 (8), p.734-734

Valiquette, G.

2010

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

IDrugs : the investigational drugs journal, 2008-12, Vol.11 (12), p.906

Gallwitz, Baptist

2008

Link zum Volltext

Verfügbarkeit prüfen

No heart risk--or benefit--from diabetes drug Onglyza

Harvard heart letter, 2013-12, Vol.24 (4), p.8

2013

Link zum Volltext

Verfügbarkeit prüfen

DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia

Pharmazie in unserer Zeit, 2010-03, Vol.39 (2), p.114-118

Gallwitz, Baptist

2010

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin in type 2 diabetes

Drugs of today (Barcelona, Spain : 1998), 2010-02, Vol.46 (2), p.101-108

Billiones, Raquel

2010

Link zum Volltext

Verfügbarkeit prüfen

New Therapeutic Horizons: Mapping the Future of Glycemic Control With Incretin-based Therapy

The Diabetes educator, 2009-09, Vol.35 (5), p.731-747

2009

Link zum Volltext

Verfügbarkeit prüfen

New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)

Der Internist (Berlin), 2014-07, Vol.55 (7), p.859-862

2014

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin + metformin. Mostly disadvantages

Prescrire international, 2013-02, Vol.22 (135), p.40-40

2013

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin and tuberculosis

Prescrire international, 2013-01, Vol.22 (134), p.17-17

2013

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions

Prescrire international, 2011-02, Vol.20 (113), p.33-37

2011

Link zum Volltext

Verfügbarkeit prüfen

Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon

Journal of managed care pharmacy, 2009-10, Vol.15 (8), p.696-700

2009

Link zum Volltext

Verfügbarkeit prüfen

New hypoglycemic agents in type 2 diabetes

La revue du praticien, 2010-04, Vol.60 (4), p.495

2010

Link zum Volltext

Verfügbarkeit prüfen

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Diabetes, obesity & metabolism, 2014-05, Vol.16 (5), p.443-450

2014

Link zum Volltext

Verfügbarkeit prüfen

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.61-71

2022

Link zum Volltext

Verfügbarkeit prüfen

Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study

Diabetes, obesity & metabolism, 2024-05, Vol.26 (5), p.1670-1677

2024

Link zum Volltext

Verfügbarkeit prüfen

Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies

Journal of managed care pharmacy, 2014-02, Vol.20 (2), p.120-129

Davidson, Jaime A

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 23 von 23

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

ThemaAged

ThemaDiabetes Mellitus, Type 2 - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(16)

Publikationsform

Artikel
(22)
magazinearticle
(1)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Baseline differences in the SAVOR trial

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis

Saxagliptin and Heart Failure in the SAVOR-TIMI 53 Trial: Reflections on the Bradford Hill Criteria

Saxagliptin efficacy

Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

No heart risk--or benefit--from diabetes drug Onglyza

DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia

Saxagliptin in type 2 diabetes

New Therapeutic Horizons: Mapping the Future of Glycemic Control With Incretin-based Therapy

New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)

Saxagliptin + metformin. Mostly disadvantages

Saxagliptin and tuberculosis

Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions

Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon

New hypoglycemic agents in type 2 diabetes

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy

Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study

Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies

Aktive Filter

Suchergebnisse filtern